Knee osteoarthritis Musculoskeletal Diseases Osteoarthritis
Conditions
Interventions
Patients with knee osteoarthritis are randomly allocated into either CO2 laser moxibustion or traditional moxibustion groups.
Patients will receive CO2 laser moxibustion or traditiona
at its base is an adhesive membrane. During treatment, the device is placed at an acupoint, and the moxa is burned about 8 mm above the skin.
Both groups have 20 minutes of treatment.
Sponsors
Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 50 to 75 undergoing conventional knee osteoarthritis treatment
Exclusion criteria
Exclusion criteria: 1. Knee pain caused by other diseases (such as rheumatoid arthritis, fibromyalgia syndrome, chronic fatigue syndrome, and ankylosing spondylitis) 2. Treatment with steroid drugs in the past 3 months 3. Received acupuncture or moxibustion treatment in the past 3 months 4. Intra-articular injection of hyaluronate in the past 6 months 5. Joint puncture or arthroscopy in the past year 6. Previous (or planned for during the trial) knee or hip replacement surgery 7. Use of other topical treatments for osteoarthritis of the knee 8. Diagnosis of any serious diseases including, but not limited to, heart disease, lung disease, kidney disease, liver disease, malignant tumor, systemic infection, infectious disease, and/or mental illness 9. Participation in another clinical study in the past month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee pain, measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at baseline and 2, 4, 8, 12, and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Knee function measured using the WOMAC function score at baseline, weeks 2, 4, 8, 12, and 24 weeks 2. Knee stiffness measured using the WOMAC stiffness score at baseline, weeks 2, 4, 8, 12, and 24 weeks 3.Knee osteoarthritis symptoms measured using the WOMAC total score at baseline, weeks 2, 4, 8, 12, and 24 weeks 4. Knee pain measured using the Visual Analogue Scale (VAS) pain score at baseline, weeks 2,4, 8, 12, and 24 weeks 5. The 50-yard walking time was assessed and recorded among the participants at baseline, weeks 4 and 12weeks to observe improvements in walking. 6. Quality of life measured using the 36-Item Short Form Health Survey (SF-36) at 4, 12 and 24 weeks and the Quality of Life Scale (QOLS) at 4 weeks 7. Participant perception of the safety of the treatment measured by investigator question (with possible answers of: safe, less safe, safety problem, or serious safety problem) at 4 weeks | — |
Countries
China
Contacts
Public ContactJing Fang
Outcome results
None listed